GS-5885

DRUG5 trials

Sponsors

Gilead Sciences

Conditions

Chronic Hepatitis CHCV InfectionHepatitis C, Chronic

Phase 1

A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C

CompletedNCT01193478

Gilead SciencesHCV Infection

Start: 2010-08-31End: 2011-12-31Updated: 2013-01-21

Phase 2

GS 5885 Administered Concomitantly With GS-9451, Tegobuvir and Ribavirin (RBV) in Chronic Genotype 1 Hepatitis C Virus (HCV) Infection

CompletedNCT01353248

Gilead SciencesHepatitis C, Chronic

Start: 2011-05-31End: 2013-03-31Updated: 2013-12-20

GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus

CompletedNCT01356160

Gilead SciencesHepatitis C, Chronic

Start: 2011-07-31End: 2013-06-30Updated: 2014-02-03

GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype

TerminatedNCT01384383

Gilead SciencesChronic Hepatitis C

Start: 2011-08-31End: 2013-06-30Updated: 2014-02-03

GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection

CompletedNCT01435226

Gilead SciencesHepatitis C, Chronic

Start: 2011-09-30End: 2013-07-31Updated: 2013-12-17

Related Papers

Characterization of Hepatitis C Virus Resistance from a Multiple-Dose Clinical Trial of the Novel NS5A Inhibitor GS-5885

Antimicrobial Agents and Chemotherapy2013-07-2395 citations